ArticleFrontiers in oncology2025
Transcriptome-based immune subtypes reveal the heterogeneity of tumor microenvironment in pediatric B-cell acute lymphocytic leukemia.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Increasing evidence highlights the important role of the tumor microenvironment (TME) in B-cell acute lymphocytic leukemia (B-ALL). Our study aimed to stratify B-ALL based on immune signatures, thus helping to clinically predict prognosis and guide treatment. Methods: Two cohorts of pediatric B-ALLs were included in this study, one from the GEO database (n = 136) was used to establish consensus clustering algorithm to stratify B-ALLs based on immune-related genes (IRGs), and the other from our cohort (n = 73) was used to validate the universality of established clustering algorithm. To elucidate the characteristics of each subtype, the prognosis, immune features, clinical information and genetic abnormalities were explored. Results: Based on the expression of 1315 IRGs, B-ALLs were classified into five distinct immune subtypes. Cluster1 had the favorable prognosis while cluster 2-5 had relatively unfavorable prognosis. Cluster 1 was strongly associated with clinical information indicative of a favorable prognosis [e.g. low white blood count (WBC) level] relative to cluster 2-5. In term of immune features, cluster 5 were characterized by high expression of multiple immune checkpoint genes [e.g. B and T lymphocyte attenuator ( Conclusions: Our study identified five immune subtypes that associated with distinct biological aberrations and clinical behaviors, which help us better understand the heterogeneity of TME and may provide valuable information for the precision therapy of pediatric B-ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.